Fig. 1: CONSORT diagram of clinical trial. | British Journal of Cancer

Fig. 1: CONSORT diagram of clinical trial.

From: The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study

Fig. 1

Intention-to-treat population was 120 patients with metastatic colorectal cancer (mCRC), and per-protocol analysis involved 108 patients. Collection was from January 2018 to June 2020, and database was locked for final analysis on June 30, 2020. Median follow-up time was 26.5 months (interquartile range [IQR], 17.0–37.0 months). Reversion to RAS wild-type by ctDNA testing was 0% during the cetuximab-based treatment.

Back to article page